Pre-operative Neoadjuvant Therapy Combined With Surgery for Treating Stage III Hepatocellular Carcinoma
The purpose of present study is to evaluate whether per-operative neoadjuvant therapy combined with surgery could improve the 1-year disease-free survival of stage III hepatocellular carcinoma patients.
Hepatocellular Carcinoma Stage III
PROCEDURE: Transhepatic Arterial Chemotherapy And Embolization (TACE)|PROCEDURE: Surgery
1-year disease free survival, 1 year
1-year overall survival, 1 year|Rate of R0 resection, 1 week|objective response rate, up to 2 months
The purpose of present study is to evaluate whether per-operative neoadjuvant therapy combined with surgery could improve the 1-year disease-free survival of stage III hepatocellular carcinoma patients.